Germany's Stratec 9M sales fall, but cost cuts lift margins

By Reuters News


Overview

  • Germany diagnostics systems maker's 9M/2026 sales fell 5% at constant currency

  • Adjusted EBIT margin rose to 8.3% from 7.3%, driven by cost cuts and higher gross margin

  • Sales decline mainly due to lower Service Parts and Consumables demand, seen as temporary


Outlook

  • Stratec sees 2026 sales stable to slightly higher on constant-currency basis for continuing ops

  • Company forecasts 2026 adjusted EBIT margin of 13.0% to 15.0%

  • Stratec expects 2026 investments at 5.0% to 7.0% of sales for continuing operations


Result Drivers

  • SERVICE PARTS AND CONSUMABLES WEAKNESS - Lower sales in Service Parts and Consumables divisions due to customers optimizing logistics and inventory after ownership changes; company expects this to be temporary but timing of recovery is uncertain

  • COST DISCIPLINE - Higher adjusted EBIT margin attributed to cost cuts, product mix, and currency effects

  • SYSTEMS SALES GROWTH - Slight increase in Systems sales driven by higher volumes in immunodiagnostics and molecular diagnostics systems


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Adjusted EPS

EUR 0.62

9M Adjusted Net Income

EUR 7.51 mln

9M Adjusted EBIT

EUR 13.66 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Stratec Se is €24.75, about 5.4% below its November 11 closing price of €26.15

  • The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 12 three months ago


Reuters Recommended Reads

  • Nov 10 - German photonics group Jenoptik's 9-month sales, profit rise on strong demand, cost cuts

  • Nov 10 - Germany's Infineon Q4 revenue rises sequentially

  • Nov 11 - Germany's Adesso 9-month sales rise 13%, EBITDA up 26%


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.